Cologne Esophageal Response Prediction Study (CERP-Study)
Conditions
Esophageal Cancer
Conditions: official terms
Esophageal Neoplasms
Conditions: Keywords
esophagus, chemoradiation, excision repair cross-complementing gene, polymorphism, response prediction
Study Type
Interventional
Study Phase
N/A
Study Design
Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Diagnostic
Intervention
Name: ERCC1 pathways analysis
Type: Genetic
Overall Status
Recruiting
Summary
RATIONALE: The prognosis of patients with advanced esophageal cancer may be improved by preoperative chemoradiation. But only those patients have a benefit from this additional therapy, whose tumor shows a response after chemoradiation. Molecular markers may help to identify before starting the therapy those patients who response.

PURPOSE: This is the first prospective, clinical trial to study the impact of ERCC1 to predict histopathological response to neoadjuvant radiochemotherapy (RTx/CTx) in patients with cancer of the esophagus.
Criteria for eligibility
Healthy Volunteers: No
Maximum Age: N/A
Minimum Age: 18 Years
Gender: Both
Criteria: Inclusion Criteria:

- informed consent

- newly diagnosed adenocarcinoma or squamous cell carcinoma of the esophagus or cardia

Exclusion Criteria:

- missing informed consent

- prior radiation or chemotherapy

- second malignancy
Location
Department of General, Visceral and Cancer Surgery, University of Cologne
Cologne, NRW, Germany
Status: Recruiting
Start Date
August 2009
Completion Date
August 2015
Sponsors
Elfriede Bollschweiler
Source
University of Cologne
Record processing date
ClinicalTrials.gov processed this data on July 28, 2015
ClinicalTrials.gov page